CytoSorbents Q2 adjusted loss narrows on cost controls
CTSO•Outlook
- Company says it remains on track toward operating cash flow breakeven in H2 2026
- CytoSorbents plans to add 3-5 sales representatives in Germany through early 2027
- Company anticipates submitting a new De Novo application for DrugSorb-ATR in early 2027
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $9.63 mln | $9.35 mln (2 Analysts) |
| Q2 Adjusted Loss Per Share | Meet | $0.05 | $0.05 (2 Analysts) |
| Q2 Loss Per Share | $0.07 | ||
| Q2 Gross Margin | 73.00% |
- The one available analyst rating on the shares is "hold"
- The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
- Wall Street's median 12-month price target for CytoSorbents Corp is , about above its August 5 closing price of
